James H. Mackaness, a seasoned medical device and operations executive, has been named chief financial officer (CFO) of Invuity, Inc. Mackaness has amassed more than 20 years of experience, and specializes in financial and strategic planning, public reporting and controls, mergers and acquisitions, and operations management within the medical device and technology industries.
James H. Mackaness: New CFO at Invuity

“We are very pleased to have Jim joining Invuity at this time as he brings a rare combination of skills that is well suited to our company profile, ” said Philip Sawyer, president and CEO of Invuity, in the August 10, 2015 news release.
According to the news release, “Most recently, Mackaness served as Chief Financial Officer and Chief Operating Officer for Mountain View, Calif.-based IRIDEX Corp., a publicly traded medical device company. Prior to IRIDEX, Mackaness was the CFO at two privately held companies one of which was sold to Cisco Systems where he went on to assume a business development role. Early in his career, he was an audit manager for Ernst & Young LLP.”
Mackaness told OTW, “Invuity is filling an important unmet need that has the potential to transform the standard of care in surgery. Going public is a huge milestone for the company, and a critical step towards becoming the market leader in surgical illumination technology. I am excited to work with Philip, the team, and our partners to continue driving the company’s business forward.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.